225.1 HLA-driven immunosuppression in living-related kidney transplantation. A protocol for low-income countries
Prof. Mirza Naqi Zafar, Pakistan
225.2 Outcomes of mTOR Inhibitors Switch for Cutaneous and/or Anogenital Warts Among Kidney Transplant Recipients
Dr. Cansu Erel Gezegen, Turkey
225.3 Randomized phase 2 trial of felzartamab in humoral transplant rejection
Dr. Katharina A Mayer, Austria
225.4 CCR5 Blockade: A novel, safe, and efficacious addition to the immunosuppressive armamentarium following kidney transplantation
Dr. Audrey Brown, United States
225.5 Quantiferon®-monitor as a biomarker of immunosuppression and predictor of infection: A scoping review
Camille N. Kotton, United States
225.6 Targeting BCL6-mediated responses to inhibit allogeneic T follicular helper cell functions
Mr. Rens Kraaijeveld, Netherlands
225.7 Tacrolimus metabolism and kidney transplant outcomes
Prof. Caner Süsal, Turkey
225.8 Polymorphisms in molecules regulating follicular helper T cell differentiation predict de novo donor specific antibody formation after liver transplantation
Dr. Kosuke Ono, Japan
225.9 Delayed Immune Tolerance for Cardiac Allografts in Nonhuman Primates by Targeting CD154, CD2, and CD28 Costimulation Pathways
Dr. Sho Takemoto, United States
225.11 Enhancing immunosuppressive medication adherence through a personal optimized system -- Right time and Right dose mobile application